mp.weixin.qq.com· 良医汇肿瘤资讯·· 4 hours agoScore71
NMPA Approves T-DXd for HER2 IHC 3+ Pan-Tumor Indication; Wu Xiaohua Discusses Impact on Gynecologic Cancer Care
【4276】吴小华教授：T‑DXd HER2 IHC 3+泛实体瘤适应症国内获批，开启妇科肿瘤精准治疗新篇章
In brief
On October 20, 2026, trastuzumab deruxtecan (T-DXd) received conditional approval from China's National Medical Products Administration (NMPA) as a single agent for adults with unresectable or metastatic HER2 IHC 3+ solid tumors who have received prior treatment or have no satisfactory alternative options.
Source: mp.weixin.qq.com · mp.weixin.qq.com